Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s. - Wikidata - wikimedia - TriplyDB

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s.

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s.

http://www.wikidata.org/entity/Q37305570

about

Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update.Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.Immune reconstitution in ART treated, but not untreated HIV infection, is associated with abnormal beta cell function.Insulin Resistance in HIV-Patients: Causes and Consequences

P2860

Q53691000-651CF12D-A040-4161-89CA-384707C42D14 Q55279874-55802321-387F-4025-A900-8D417681D738 Q55342018-20FD0907-9085-4C7E-9785-072C5522234B Q58763014-627B4E9A-2D51-4850-A8E9-43DB9368C5EC

P2860

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s.

http://www.wikidata.org/entity/Q37305570

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Changes in Insulin Resistance ...... Clinical Trials Group A5260s.

@en

Changes in Insulin Resistance ...... Clinical Trials Group A5260s.

@nl

type

label

Changes in Insulin Resistance ...... Clinical Trials Group A5260s.

@en

Changes in Insulin Resistance ...... Clinical Trials Group A5260s.

@nl

prefLabel

Changes in Insulin Resistance ...... Clinical Trials Group A5260s.

@en

Changes in Insulin Resistance ...... Clinical Trials Group A5260s.

@nl

P1433

Q37305570-8C1AFB52-02DB-45B5-8526-1FB311F1FD0B

P1476

Q37305570-EBEF8733-D54A-4CCF-8A6A-C68352E44CDD

P2093

Q37305570-23658D1F-4188-41D3-BE15-175E0BE144C2

Q37305570-275F2F40-08C2-48F1-A802-822BDEFFE5F7

Q37305570-B35336DE-61B1-4F01-9548-36CC1E0588F1

Q37305570-CF0B0312-50CF-47B9-9FFF-1FDFDC49CE2D

Q37305570-D0FD6AF7-01A3-4CF2-9533-4501A03263B6

Q37305570-FC863D0A-94D2-4A48-B254-AB2D4C140563

Q37305570-FFBDF45E-D424-4678-88FC-5F348CB1F600

P2860

Q37305570-028E6157-B326-4C46-A4B2-9B88E784B0C7

Q37305570-0366EC28-624D-4A73-9512-C5EEC537EA16

Q37305570-060B601E-D99B-497D-85F4-1A8FE2142C1D

Q37305570-06EB3A0C-89AC-4C4A-A354-F2BFAC02B0D3

Q37305570-0C6FB4C3-49DA-4850-880A-5D79E2D24275

Q37305570-129D12B7-D896-49DE-9844-235A980B6693

Q37305570-12BBD2AA-58F3-43BB-A340-5C41609DE06C

Q37305570-1845F363-0A95-4AB8-96F9-502E781892AE

Q37305570-1D424D2D-4331-4370-AE9A-A0F4C482B3FB

Q37305570-223C4146-A4E4-477F-BA4B-397746D65AA2

P304

Q37305570-0EA635CD-1DBD-4F37-85B2-9D17BE9E3F04

P31

Q37305570-71AAD030-9147-4185-A044-FD298B803522

P356

Q37305570-44EFFCE4-D85E-4A07-BE96-678E7A189FE3

P433

Q37305570-8AE31397-2DD5-47A1-8FFC-6318AAE4920A

P478

Q37305570-0F3681CC-877E-4FDF-B984-D2A336F97388

P50

Q37305570-D226794F-36D8-4E98-AE98-BEFC3BC61CE4

P577

Q37305570-BB3148C0-3D33-4C9B-97F5-3F8B01262D2D

P698

Q37305570-5BA71B3D-6D45-400B-8671-A3F0A60939B7

P921

Q37305570-09712A95-689C-488C-B474-CFA755B109C6

P932

Q37305570-A6AC63C3-360C-4149-BD9A-C7DE0ACDA09D

P356

P1433

Open forum infectious diseases

P1476

Changes in Insulin Resistance ...... Clinical Trials Group A5260s.

@en

P2093

Carlee Moser

http://www.w3.org/2001/XMLSchema#string

Grace A McComsey

http://www.w3.org/2001/XMLSchema#string

Judith Currier

http://www.w3.org/2001/XMLSchema#string

Michael P Dube

http://www.w3.org/2001/XMLSchema#string

Sahera Dirajlal-Fargo

http://www.w3.org/2001/XMLSchema#string

Theodoros Kelesidis

http://www.w3.org/2001/XMLSchema#string

Todd T Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Metabolic effects of indinavir in healthy HIV-seronegative men

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).

Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study.

Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study.

No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial

Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.

Impact of randomized antiretroviral therapy initiation on glucose metabolism

P304

ofw174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/OFID/OFW174

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27704026

http://www.w3.org/2001/XMLSchema#string

P921

P932

5047417

http://www.w3.org/2001/XMLSchema#string